SCHEMBL16717433

SCHEMBL16717433

Cc1ccc2c(Oc3ccccc3)cccc2n1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA1 P30542 1/20 0.52
HTT P42858 3/20 0.47
LMNA P02545 1/20 0.47
HTR1A P08908 3/20 0.47
HTR1D P28221 3/20 0.47
HTR1B P28222 3/20 0.47
KMT2A Q03164 3/20 0.46
MEN1 O00255 2/20 0.46
POLB P06746 1/20 0.46
KDM4E B2RXH2 1/20 0.46
GLA P06280 1/20 0.46
MAPT P10636 1/20 0.46
CYP1A2 P05177 2/20 0.46
MIF P14174 1/20 0.45
ALDH1A1 P00352 2/20 0.45
TSHR P16473 1/20 0.43
ELANE P08246 1/20 0.43
GRM5 P41594 1/20 0.41
KCNH2 Q12809 1/20 0.41
BRAF P15056 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7532440 0.81 CYP1A2 (0.56) ADORA1HTTLMNAKMT2AMEN1
SCHEMBL2757271 0.80 POLB (0.56) ADORA1LMNAHTR1AHTR1DHTR1B
SCHEMBL18024086 0.79 MAPT (0.46) HTTLMNAKMT2AKDM4EGLA
SCHEMBL17980807 0.76 GRM5 (0.48) HTTLMNAKMT2APOLBKDM4E
SCHEMBL16716854 0.74 ADORA1 (0.48) ADORA1HTTLMNAKMT2AMEN1
SCHEMBL18024090 0.74 GRM5 (0.53) ADORA1HTTLMNAKMT2AMEN1
SCHEMBL14740604 0.74 GLA (0.53) HTTLMNAKMT2APOLBKDM4E
SCHEMBL18024165 0.74 ERBB2 (0.49) HTTLMNAKMT2APOLBKDM4E
SCHEMBL20333258 0.73 GRM5 (0.52) ADORA1HTTLMNAKMT2APOLB
SCHEMBL10250716 0.73 NCF1 (0.53) ADORA1HTTLMNAKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230061891-A1 TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS FORMA THERAPEUTICS, INC. 2023-03-02 US disclosed
US-20230061891-A1 TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS FORMA THERAPEUTICS, INC. 2023-03-02 US disclosed
US-11111229-B2 Tetrahydroquinoline compositions as BET bromodomain inhibitors FORMA THERAPEUTICS, INC. (US) 2021-09-07 US disclosed
US-11111229-B2 Tetrahydroquinoline compositions as BET bromodomain inhibitors FORMA THERAPEUTICS, INC. (US) 2021-09-07 US disclosed
EP-3799872-A1 TETRAHYDROQUINOLINE DERIVATIVES FOR USE AS BET INHIBITORS Forma Therapeutics, Inc. (US) 2021-04-07 EP disclosed
EP-3799872-A1 TETRAHYDROQUINOLINE DERIVATIVES FOR USE AS BET INHIBITORS Forma Therapeutics, Inc. (US) 2021-04-07 EP disclosed
EP-3071203-B1 TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS FORMA THERAPEUTICS INC (US) 2020-12-23 EP disclosed
EP-3071203-B1 TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS FORMA THERAPEUTICS INC (US) 2020-12-23 EP disclosed
US-20200369642-A1 TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS FORMA THERAPEUTICS, INC. 2020-11-26 US disclosed
US-20200369642-A1 TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS FORMA THERAPEUTICS, INC. 2020-11-26 US disclosed
US-20160256448-A1 TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS FORMA THERAPEUTICS, INC. 2016-09-08 US disclosed
CN-105934246-A Tetrahydroquinoline compositions as BET bromodomain inhibitors 福马疗法公司 2016-09-07 CN disclosed
US-9388161-B2 Tetrahydroquinoline compositions as BET bromodomain inhibitors FORMA THERAPEUTICS, INC. (US) 2016-07-12 US disclosed
US-9388161-B2 Tetrahydroquinoline compositions as BET bromodomain inhibitors FORMA THERAPEUTICS, INC. (US) 2016-07-12 US disclosed
US-9388161-B2 Tetrahydroquinoline compositions as BET bromodomain inhibitors FORMA THERAPEUTICS, INC. (US) 2016-07-12 US disclosed
US-20150232445-A1 TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS FORMA THERAPEUTICS, INC. 2015-08-20 US disclosed
US-20150232445-A1 TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS FORMA THERAPEUTICS, INC. 2015-08-20 US disclosed
US-20150232445-A1 TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS FORMA THERAPEUTICS, INC. 2015-08-20 US disclosed
WO-2015074064-A2 TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS BAIR KENNETH W (US) 2015-05-21 WO disclosed
WO-2015074064-A2 TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS BAIR KENNETH W (US) 2015-05-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160256448-A1 TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS BRD4, BRD3, BRD1 ADORA1 3026/4885HTT 1836/4885LMNA 2940/4885
US-11111229-B2 Tetrahydroquinoline compositions as BET bromodomain inhibitors BRD4, BRD3, BRD1 ADORA1 3026/4885HTT 1836/4885LMNA 2940/4885
US-20200369642-A1 TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS BRD4, BRD3, BRD1 ADORA1 3026/4885HTT 1836/4885LMNA 2940/4885
US-20150232445-A1 TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS BRD4, BRD3, BRD1 ADORA1 3026/4885HTT 1836/4885LMNA 2940/4885
US-20230061891-A1 TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS BRD4, BRD3, BRD1 ADORA1 3026/4885HTT 1836/4885LMNA 2940/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.